Location Directory

Clinical trials in Rochester, Minnesota

This page shows live ClinicalTrials.gov search results for Rochester, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9154

Shown on this page

Current sort

Institutions in Rochester

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions: Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Months
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more

Conditions: SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Interventions: CRN09682; Drug
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Duarte, California • Newport Beach, California + 19 more

Conditions: Higher-risk Myelodysplastic Syndrome
Interventions: Lisaftoclax (APG-2575), Azacitidine Injection, Placebo; Drug · Other
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more

Conditions: Atrial Fibrillation
Interventions: Apple Watch; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-alcoholic Steatohepatitis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 130
States / cities: Huntsville, Alabama • Chandler, Arizona • Peoria, Arizona + 100 more

Conditions: Lichen Sclerosus
Interventions: Delgocitinib, Cream Vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 16 more

Conditions: Diabetes type2, Obesity
Interventions: RESET Liner, Sham; Device · Other
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 27
States / cities: Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more

Conditions: Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions: [203Pb]VMT01, [212Pb]VMT01, Nivolumab; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 16
States / cities: Orange, California • Jacksonville, Florida • Miami, Florida + 12 more

Conditions: Biliary Tract Cancer
Interventions: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan, Rilvegostomig; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 48
States / cities: Scottsdale, Arizona • Tucson, Arizona • Fullerton, California + 38 more

Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions: Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri

Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Interventions: Sponge Capsule; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,526 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 8
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Austin, Minnesota + 5 more

Clinical trials in Rochester, Minnesota

Filter and sort this location

Institutions in Rochester

Live official records

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

Realtime Diagnosis From Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation With Long Follow-Up (REGAL)

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus

The RESET System Pivotal Clinical Trial (Protocol Revision K)

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma